Amicus Therapeutics, Inc.
FOLD
Xếp hạng trong cổ phiếu
#3669
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Giá cổ phiếu
$14.49
Đồng bộ lần cuối: 2026-04-27
Vốn hóa thị trường
$4.55B
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
69.47%
Quốc gia
US
Giao dịch Amicus Therapeutics, Inc. (FOLD)
Danh mục
Healthcare
Lịch sử giá cổ phiếu của Amicus Therapeutics, Inc. (FOLD)
Giá đóng cửa cao nhất: $14.46 vào 2026-04-01
Giá đóng cửa thấp nhất: $14.43 vào 2007-05-01
Giá đóng cửa thấp nhất: $14.43 vào 2007-05-01
Lịch sử giá cổ phiếu của Amicus Therapeutics, Inc. từ 2007 đến 2026
Hiệu suất giá cổ phiếu hàng năm
| Năm | Hiệu suất |
|---|---|
| 2026 (TTM) | 9.92% |
| 2025 | 19.21% |
| 2024 | -21.90% |
| 2023 | 3.81% |
| 2022 | 8.63% |
| 2021 | -52.22% |
| 2020 | 134.59% |
| 2019 | 0.48% |
| 2018 | -26.50% |
| 2017 | 150.91% |
| 2016 | -44.82% |
| 2015 | 19.71% |
| 2014 | 274.05% |
| 2013 | -52.64% |
| 2012 | 39.12% |
| 2011 | -22.66% |
| 2010 | 11.06% |
| 2009 | -51.83% |
| 2008 | -42.25% |
| 2007 | 0.00% |
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
| Công ty | Giá cổ phiếu | Thay đổi 1năm% | Quốc gia |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.89 | -3.74% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
